"Herpes Zoster" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)
| Descriptor ID |
D006562
|
| MeSH Number(s) |
C02.256.466.930.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Herpes Zoster".
Below are MeSH descriptors whose meaning is more specific than "Herpes Zoster".
This graph shows the total number of publications written about "Herpes Zoster" by people in this website by year, and whether "Herpes Zoster" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 4 | 0 | 4 |
| 2012 | 2 | 1 | 3 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 1 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 4 | 0 | 4 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 4 | 0 | 4 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Herpes Zoster" by people in Profiles.
-
Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged =50 years in the United States. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2327145.
-
Herpes zoster diagnosis and treatment in relation to incident dementia: A population-based retrospective matched cohort study. PLoS One. 2024; 19(1):e0296957.
-
Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. BMJ. 2023 Nov 08; 383:e076321.
-
Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine. Vaccine. 2023 Jul 05; 41(30):4392-4401.
-
Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data. Am J Epidemiol. 2023 Feb 01; 192(2):205-216.
-
Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):643-649.
-
In older adults, use of a recombinant zoster vaccine was associated with Guillain-Barré syndrome. Ann Intern Med. 2022 03; 175(3):JC35.
-
Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 2021 02 05; 39(6):926-932.
-
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. J Manag Care Spec Pharm. 2020 Dec; 26(12):1567-1575.
-
The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults =50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence. J Infect Dis. 2020 08 04; 222(5):798-806.